In GSCs isolated from two different human glioma xenografts (Figure 4A) and directly from a patient specimen (Figure 4B), introduction of A20-directed shRNA increased the percentage of Annexin V–positive cells when compared to nontargeting control shRNA. The gene discussed is ANXA5; the disease is central nervous system cancer.